Kabadi Rajiv A, Shah Mital, Marhefka Gregary D, George Gautam, Awsare Bharat, Terai Mizue, Sato Takami
Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania 19107.
Department of Medicine, Division of Cardiology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania 19107.
Tex Heart Inst J. 2020 Jun 1;47(3):224-228. doi: 10.14503/THIJ-18-6762.
Locoregional cytokine treatment, or immunoembolization, is an experimental targeted therapy for uveal melanoma metastatic to the liver. Unlike systemic cytokine treatments that have been associated with substantial toxicity, this method of drug delivery appears to be better tolerated. Because this newer therapy is being prescribed more widely, oncologists, interventional radiologists, cardiologists, pulmonologists, critical care specialists, and other providers should become familiar with potential adverse reactions. We describe the case of a 67-year-old man who had metastatic uveal melanoma. Before he underwent liver-directed immunoembolization, he had elevated markers of endothelial dysfunction. He died after the rapid onset of acute right ventricular failure from severe pulmonary hypertension with possible superimposed isolated right ventricular takotsubo cardiomyopathy. In discussing this rare case, we focus on the differential diagnosis.
局部区域细胞因子治疗,即免疫栓塞,是一种针对转移性至肝脏的葡萄膜黑色素瘤的实验性靶向治疗方法。与具有显著毒性的全身细胞因子治疗不同,这种给药方法似乎耐受性更好。由于这种新疗法的应用越来越广泛,肿瘤学家、介入放射科医生、心脏病学家、肺科医生、重症监护专家和其他医疗服务提供者应熟悉其潜在的不良反应。我们描述了一名67岁转移性葡萄膜黑色素瘤男性患者的病例。在他接受肝脏定向免疫栓塞治疗前,其内皮功能障碍标志物升高。他在严重肺动脉高压并可能叠加孤立性右心室应激性心肌病导致急性右心室衰竭迅速发作后死亡。在讨论这个罕见病例时,我们重点关注鉴别诊断。